Solifenacin/tamsulosin - Jeil Pharmaceutical

Drug Profile

Solifenacin/tamsulosin - Jeil Pharmaceutical

Alternative Names: JLP-1207

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jeil Pharmaceutical
  • Class Antispasmodics; Quinuclidines; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Benign prostatic hyperplasia
  • Phase I Overactive bladder

Most Recent Events

  • 25 May 2015 Jeil Pharmaceutical plans a phase I drug interaction study in healthy volunteers in South Korea (NCT02447367)
  • 01 Mar 2015 Jeil Pharmaceutical completes a pharmacokinetic drug interaction phase I trial (In volunteers) in South Korea (NCT02180997)
  • 01 Jul 2014 Preclinical trials in Benign prostatic hyperplasia and Overactive bladder in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top